Welcome to our dedicated page for XLRN news (Ticker: XLRN), a resource for investors and traders seeking the latest updates and insights on XLRN stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XLRN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XLRN's position in the market.
Acceleron Pharma (NASDAQ:XLRN) presented interim results from the PULSAR Phase 2 trial of sotatercept at the ATS 2021 conference, focusing on pulmonary arterial hypertension (PAH). Patients undergoing treatment for up to 48 weeks showed consistent or improved efficacy in critical endpoints, such as the six-minute walk distance (6MWD). Notably, sotatercept was well tolerated, with 90 out of 97 participants still enrolled. The findings suggest sotatercept's potential as a new approach to managing PAH, addressing significant unmet needs in the treatment landscape.
Acceleron Pharma (Nasdaq: XLRN) presented preliminary interim data from the SPECTRA Phase 2 trial of sotatercept for pulmonary arterial hypertension (PAH) at ATS 2021. The study involved 21 patients, showing significant improvements in key hemodynamic measures, such as a 35.9% reduction in pulmonary vascular resistance and a 29.5% reduction in mean pulmonary arterial pressure. Sotatercept was well tolerated, with treatment-emergent adverse events noted in 76% of patients, none related to the drug. The company aims to develop sotatercept as a potential backbone therapy for PAH across all disease stages.
Acceleron Pharma Inc. (Nasdaq: XLRN) announced the presentation of multiple abstracts on REBLOZYL® (luspatercept-aamt) at the 2021 European Hematology Association Virtual Congress, scheduled for June 9-17. Highlighting the event, results from the BEYOND Phase 2 trial in adults with non-transfusion dependent beta-thalassemia will be shared during the Presidential Symposium on June 11. CEO Habib Dable expressed pride in presenting new data supporting luspatercept's efficacy and safety.
Acceleron Pharma (Nasdaq:XLRN) will hold a conference call on May 19, 2021, at 10:30 a.m. EDT to discuss updates from the PULSAR and SPECTRA Phase 2 trials of sotatercept for pulmonary arterial hypertension (PAH). Notable results from PULSAR include achieving primary endpoints related to pulmonary vascular resistance and exercise capacity. Sotatercept has received Breakthrough Therapy designation from the FDA. The ongoing SPECTRA trial will further investigate its efficacy. The company's future Phase 3 studies aim to establish sotatercept as a primary treatment for PAH.
Acceleron Pharma reported its Q1 2021 financial results, showing revenue of $24.8 million, driven by $22.4 million in royalty revenue from REBLOZYL. The company continues to progress in its clinical trials, with significant advancements in PAH treatments including sotatercept, which is currently in Phase 3 trials. The cash position stood at $795.4 million, down from $857.5 million at year-end 2020, providing sufficient funding for ongoing operations. The net loss for the quarter was $63.5 million, or $1.05 per share.
Acceleron Pharma Inc. (Nasdaq:XLRN) reported net sales of REBLOZYL® (luspatercept-aamt) at approximately $112 million for Q1 2021, with expected royalty revenue of about $22.4 million, a slight decrease from Q4 2020's $23 million. The preliminary revenue figures are unaudited and subject to adjustments. Acceleron continues its focus on TGF-beta superfamily therapeutics, emphasizing its ongoing developments in pulmonary and hematologic diseases, including the advancement of sotatercept for pulmonary arterial hypertension.
Acceleron Pharma (Nasdaq:XLRN) will host a webcast and conference call on May 6, 2021, at 5:00 p.m. EDT to discuss its Q1 2021 financial results. The event will be accessible through the Company's website under 'Events & Presentations.' Acceleron focuses on developing therapies for serious diseases, notably pulmonary arterial hypertension (PAH) and blood disorders. The company reported positive results from the PULSAR Phase 2 trial for sotatercept, which aims to serve as a backbone therapy for PAH. Additionally, REBLOZYL is recognized as the first erythroid maturation agent approved in multiple regions.
Acceleron Pharma Inc. (Nasdaq: XLRN) announced updates on the PULSAR and SPECTRA Phase 2 clinical trials of its investigational treatment, sotatercept, for pulmonary arterial hypertension (PAH). Presentations at the ATS 2021 conference will include interim results from the PULSAR trial, demonstrating improvements in key endpoints such as six-minute walk distance and WHO functional class. Additionally, preclinical research will assess sotatercept's effects in animal models. The company aims to position sotatercept as a backbone therapy for PAH, having received Breakthrough Therapy designation from the FDA.
Acceleron Pharma (Nasdaq: XLRN) announced the publication of PULSAR Phase 2 trial results for sotatercept in pulmonary arterial hypertension (PAH) in the New England Journal of Medicine. The trial demonstrated a statistically significant reduction in pulmonary vascular resistance and improvement in six-minute walk distance. The STELLAR Phase 3 trial is currently enrolling patients. Sotatercept showed general tolerance among participants, and Acceleron plans further Phase 3 studies (HYPERION and ZENITH). This publication marks the third Acceleron study featured in the journal in 15 months.
Acceleron Pharma Inc. (XLRN) reported its 2020 financial results, highlighting significant milestones in its pulmonary and hematology programs. For Q4 2020, revenue was $25.9 million, boosted by $23 million in royalties from REBLOZYL sales, contributing to a total annual revenue of $92.5 million. The company also announced its advancement of sotatercept into a Phase 3 trial for PAH and plans for ACE-1334 trials in systemic sclerosis. However, it reported a net loss of $57.4 million for Q4 and $166 million for the year, against a backdrop of high R&D expenditures.
